arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Amphastar Pharmaceuticals, Inc.

AMPH
$24.98 ▲ +0.66 (+2.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Neutral
auto_awesome

Analytical Summary

Amphastar Pharmaceuticals, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.2B
Dividend Yield —
Revenue Growth -1.7% ↘
Op. Margin 19.5% ↘
ROIC 18.0% ↘
FCF / Share $2.59 ↘
Trailing P/E 11.9x
Price / Book —
FCF Yield 10.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$719.89M
↓ -1.7% —
Net Income Profit after all expenses
$98.09M
↓ -38.5% —
Operating Margin Operating profit as % of sales
19.5%
↓ -30.5% 74th
FCF / Share Free cash flow per share
$2.59
↓ -27.1% —
Long-Term Debt Long-term obligations
$619.71M
↑ +1.0% —

Health Breakdown

Profitability ↑
74
Financial Health ↓
76
Cash Quality ↑
74

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters